ArticleSleep2023
Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?
Article in Sleep, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.Journal of translational medicine · 2025Pooled it
- Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis.Sleep medicine · 2024Pooled it
- Obesity-informed OSA care: defining the expanding boundary of sleep medicine.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Article
- Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.International journal of molecular sciences · 2026Review
- The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA: A Changing Landscape?CHEST pulmonary · 2026Review
- Disordered eating in office workers is correlated with trauma, stress, emotional regulation, and sleep quality: a cross-sectional screening.AIMS public health · 2026Article
- Dietary inflammatory potential exacerbates sleep disturbances in hyperlipidemia: mediation by BMI and neuro-metabolic pathways.BMC nutrition · 2025Article
- The role of weight management in sleep disordered breathing.Breathe (Sheffield, England) · 2025Review
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?Sleep · 2025Article
- Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists.American journal of medicine open · 2025Article
- Association between body roundness index and obstructive sleep apnea: a cross-sectional study from the NHANES (2005-2008 to 2015-2020).BMC oral health · 2025Article
- A Standardized Method for Vertical Sleeve Gastrectomy Bariatric Surgery Investigations in Cancer.Frontiers in microbiomes · 2025Article
- Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions.Frontiers in neurology · 2025Review
- Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?Medicina (Kaunas, Lithuania) · 2024Review
- Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2024Review
- We Can Use Machine Learning to Predict Obstructive Sleep Apnea.American journal of respiratory and critical care medicine · 2024Article
- Association between obstructive sleep apnea and visceral adiposity index and lipid accumulation product: NHANES 2015-2018.Lipids in health and disease · 2024Article
- The association of weight loss from anti-obesity medications or bariatric surgery and apnea-hypopnea index in obstructive sleep apnea.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024Review
- Obesity hypoventilation syndrome, literature review.Sleep advances : a journal of the Sleep Research Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Obesity is a chronic disease affecting over 670 million adults globally, with multiple complications including obstructive sleep apnea (OSA). Substantial weight loss in patients with obesity-related OSA can reduce or even eliminate OSA as well as reduce sleepiness and improve cardio-metabolic health. Evidence suggests that these improvements exceed those that occur with device-based OSA therapies like continuous positive airway pressure which continue to be the first-line of therapy. Resistance to weight management as a first-line strategy to combat OSA could arise from the complexities in delivering and maintaining adequate weight management, particularly in sleep clinic settings. Recently, incretin-based pharmacotherapies including glucagon-like peptide 1 (GLP-1) receptor agonists alone or combined with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been developed to target glycemic control in type 2 diabetes. These medications also slow gastric emptying and reduce energy intake. In randomized, placebo-controlled trials of these medications in diabetic and non-diabetic populations with obesity, participants on active medication lost up to 20% of their body weight, with corresponding improvements in blood pressure, lipid levels, physical functioning, and fat mass loss. Their adverse effects are predominantly gastrointestinal-related, mild, and transient. There are trials currently underway within individuals with obesity-related OSA, with a focus on reduction in weight, OSA severity, and cardio-metabolic outcomes. These medications have the potential to substantially disrupt the management of OSA. Pending coming data, we will need to consider pharmacological weight loss as a first-line therapy and how that influences training and management guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.